These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 37787109

  • 1. Longitudinal Metabolite Changes in Progressive Multiple Sclerosis: A Study of 3 Potential Neuroprotective Treatments.
    John NA, Solanky BS, De Angelis F, Parker RA, Weir CJ, Stutters J, Carrasco FP, Schneider T, Doshi A, Calvi A, Williams T, Plantone D, Monteverdi A, MacManus D, Marshall I, Barkhof F, Gandini Wheeler-Kingshott CAM, Chataway J, MS‐SMART Investigators.
    J Magn Reson Imaging; 2024 Jun; 59(6):2192-2201. PubMed ID: 37787109
    [Abstract] [Full Text] [Related]

  • 2. NAA is a Marker of Disability in Secondary-Progressive MS: A Proton MR Spectroscopic Imaging Study.
    Solanky BS, John NA, DeAngelis F, Stutters J, Prados F, Schneider T, Parker RA, Weir CJ, Monteverdi A, Plantone D, Doshi A, MacManus D, Marshall I, Barkhof F, Gandini Wheeler-Kingshott CAM, Chataway J, MS-SMART Investigators.
    AJNR Am J Neuroradiol; 2020 Dec; 41(12):2209-2218. PubMed ID: 33154071
    [Abstract] [Full Text] [Related]

  • 3. Metabolite changes in normal-appearing gray and white matter are linked with disability in early primary progressive multiple sclerosis.
    Sastre-Garriga J, Ingle GT, Chard DT, Ramió-Torrentà L, McLean MA, Miller DH, Thompson AJ.
    Arch Neurol; 2005 Apr; 62(4):569-73. PubMed ID: 15824254
    [Abstract] [Full Text] [Related]

  • 4. Altered hypothalamic metabolism in early multiple sclerosis - MR spectroscopy study.
    Hnilicová P, Kantorová E, Poláček H, Grendár M, Bittšanský M, Čierny D, Sivák Š, Zeleňák K, Lehotský J, Dobrota D, Kurča E.
    J Neurol Sci; 2019 Dec 15; 407():116458. PubMed ID: 31622679
    [Abstract] [Full Text] [Related]

  • 5. Increased concentrations of glutamate and glutamine in normal-appearing white matter of patients with multiple sclerosis and normal MR imaging brain scans.
    Tisell A, Leinhard OD, Warntjes JB, Aalto A, Smedby Ö, Landtblom AM, Lundberg P.
    PLoS One; 2013 Dec 15; 8(4):e61817. PubMed ID: 23613944
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Multi-voxel magnetic resonance spectroscopy of cerebral metabolites in healthy adults at 3 Tesla.
    Doelken MT, Mennecke A, Stadlbauer A, Kloska S, Struffert T, Engelhorn T, Thuerauf N, Doerfler A, Stefan H, Hammen T.
    Acad Radiol; 2009 Dec 15; 16(12):1493-501. PubMed ID: 19781961
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
    Chataway J, De Angelis F, Connick P, Parker RA, Plantone D, Doshi A, John N, Stutters J, MacManus D, Prados Carrasco F, Barkhof F, Ourselin S, Braisher M, Ross M, Cranswick G, Pavitt SH, Giovannoni G, Gandini Wheeler-Kingshott CA, Hawkins C, Sharrack B, Bastow R, Weir CJ, Stallard N, Chandran S, MS-SMART Investigators.
    Lancet Neurol; 2020 Mar 15; 19(3):214-225. PubMed ID: 31981516
    [Abstract] [Full Text] [Related]

  • 11. Metabolite changes in early relapsing-remitting multiple sclerosis. A two year follow-up study.
    Tiberio M, Chard DT, Altmann DR, Davies G, Griffin CM, McLean MA, Rashid W, Sastre-Garriga J, Thompson AJ, Miller DH.
    J Neurol; 2006 Feb 15; 253(2):224-30. PubMed ID: 16307201
    [Abstract] [Full Text] [Related]

  • 12. Glutamatergic and Neuronal Dysfunction in Gray and White Matter: A Spectroscopic Imaging Study in a Large Schizophrenia Sample.
    Bustillo JR, Jones T, Chen H, Lemke N, Abbott C, Qualls C, Stromberg S, Canive J, Gasparovic C.
    Schizophr Bull; 2017 May 01; 43(3):611-619. PubMed ID: 27550776
    [Abstract] [Full Text] [Related]

  • 13. Case control study: magnetic resonance spectroscopy of brain in HIV infected patients.
    Bairwa D, Kumar V, Vyas S, Das BK, Srivastava AK, Pandey RM, Sharma SK, Jagannathan NR, Sinha S.
    BMC Neurol; 2016 Jul 12; 16():99. PubMed ID: 27405321
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis.
    Chard DT, Griffin CM, McLean MA, Kapeller P, Kapoor R, Thompson AJ, Miller DH.
    Brain; 2002 Oct 12; 125(Pt 10):2342-52. PubMed ID: 12244090
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Hypothalamic damage in multiple sclerosis correlates with disease activity, disability, depression, and fatigue.
    Kantorová E, Poláček H, Bittšanský M, Baranovičová E, Hnilicová P, Čierny D, Sivák Š, Nosáľ V, Zeleňák K, Kurča E.
    Neurol Res; 2017 Apr 12; 39(4):323-330. PubMed ID: 28191860
    [Abstract] [Full Text] [Related]

  • 20. Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis.
    Connick P, De Angelis F, Parker RA, Plantone D, Doshi A, John N, Stutters J, MacManus D, Prados Carrasco F, Barkhof F, Ourselin S, Braisher M, Ross M, Cranswick G, Pavitt SH, Giovannoni G, Gandini Wheeler-Kingshott CA, Hawkins C, Sharrack B, Bastow R, Weir CJ, Stallard N, Chandran S, Chataway J, UK Multiple Sclerosis Society Clinical Trials Network.
    BMJ Open; 2018 Aug 30; 8(8):e021944. PubMed ID: 30166303
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.